A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.

Clinical trial NCT01323270 · COMPLETED

Trial details

NCT number: NCT01323270
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Meningococcal Vaccine rLP2086 Repevax N Meningitidis Serogroup B Meningitis

Start date: 2011-03-18
Primary completion: 2012-10-08
Enrollment: 753

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.